Mubadala Bio strengthens UAE drug security with local hormone therapy launch

UAE—Mubadala Bio, a life sciences company dedicated to advancing better health outcomes for the UAE and beyond, has announced that its subsidiary, Bioventure Healthcare, has launched dydrogesterone, an in-demand hormone therapy.

The launch represents a significant expansion of the organization’s women’s health portfolio, which stands as one of its core therapy areas.

The timing of this announcement holds particular significance, as it follows Bioventure Healthcare’s recent achievement of European Union Good Manufacturing Practice (EU GMP) certification.

The company obtained this prestigious certification after comprehensive on-site inspections, placing it among a select group of UAE-based manufacturers that hold this distinguished credential.

This certification validates the company’s commitment to maintaining the highest standards of pharmaceutical manufacturing.

Understanding Dydrogesterone’s medical applications

Dydrogesterone serves as a synthetic form of progesterone and plays a crucial role in supporting hormone balance in women.

Healthcare providers commonly prescribe this medication to help manage certain fertility-related conditions and menstrual disorders.

The availability of this treatment addresses growing needs in reproductive health, an area that has become increasingly important due to broader demographic and societal trends.

Access to well-established, trusted therapies like dydrogesterone reinforces the foundation of comprehensive women’s healthcare.

Leadership Vision for National Health Security

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, emphasized that this milestone reflects Mubadala’s long-term commitment to building a national life sciences champion.

He explained that producing highly needed medical therapies locally strengthens the UAE’s pharmaceutical capabilities while simultaneously supporting national health priorities.

This approach reduces dependence on international supply chains and enhances the country’s healthcare resilience.

Dr. Essam Mohamed, CEO of Mubadala Bio, highlighted the broader mission behind this initiative.

He stated that Mubadala Bio supports the life sciences ecosystem in the UAE by enhancing drug security and expanding access to highly demanded treatments.

The local production of this medication aligns directly with the company’s mission to provide better health, closer to everyone who needs it.

Prioritizing women’s health across the nation

Hamad Husein Al Marzooqi, Deputy CEO of Mubadala Bio, emphasized the central importance of women’s health to the organization’s priorities and to society’s wellbeing as a whole.

He noted that bringing the production of this essential treatment closer to home improves access to key medications for women across the UAE.

The local manufacturing capability ensures consistent availability and reduces potential supply disruptions.

The local production of dydrogesterone represents not only an important milestone for Mubadala Bio and Bioventure Healthcare but also a timely contribution to supporting women’s health throughout the country.

This achievement demonstrates how strategic investment in pharmaceutical manufacturing can directly benefit patients while strengthening national healthcare infrastructure for future generations.